It was also shown that an inhibitor of the Akt1/mTOR pathway, RAD001 (Everolimus), potentiates 1,25D-induced growth arrest and differentiation of AML cells, due to the enhancement of 1,25D-mediated transcriptional activation of p21Cip1/Waf1 in association with increased level of the acetylated forms of histone H3 and VDR bound to the p21Cip1/Waf1 promoter [201]. This evidence concerns the gene AKT1 and acute myeloid leukemia.